We traveled to Washington D.C. for a State of the Science Summit on Breast Cancer, which focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.
We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.
We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.
We headed to Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma, which focused on recent advances made in the treatment landscapes.
We headed to Chicago, Illinois, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on recent updates in the field, particularly data from the 2018 World Conference on Lung Cancer.
We headed to Charlotte, North Carolina, for a State of the Science Summit on Genitourinary Cancers, which focused on the evolving paradigms of prostate cancer and renal cell carcinoma.
We headed to Clayton, Missouri for a State of the Science Summit on Hematologic Malignancies, which focused on novel agents in chronic lymphocytic leukemia, advances in acute myeloid leukemia, progress in myeloproliferative neoplasms, and more.
We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.
We visited Summit, New Jersey for a State of the Science Summit on non–small cell lung cancer (NSCLC). The meeting covered the current standard of care for early-stage lung cancer, approaches to locoregionally advanced NSCLC, updates in EGFR-positive NSCLC, and more.